Torno Capital’s Neurocrine Biosciences NBIX Stock Holding History

Torno Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,000	Closed	-$828K	–	291
2024 Q1	$828K	Buy	+6,000	New	+$819K	0.05%	125

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Torno Capital's NBIX Position: Q2 2024 in Review

Torno Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 6,000 shares — an estimated $828K sold.

Torno Capital first reported a position in NBIX in Q1 2024 and held it in 1 quarter. The position peaked at $828K in Q1 2024. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

Torno Capital reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
Torno Capital sold 6,000 Neurocrine Biosciences shares in Q2 2024, an estimated $828K.
Torno Capital first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 1 quarter.
Torno Capital's Neurocrine Biosciences position peaked at $828K in Q1 2024.
594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Torno Capital's 13F filing for Q2 2024, filed 14 Aug 2024.